Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This Phase 1 clinical trial will evaluate MIV-150, a third generation non-nucleoside reverse
transcriptase inhibitor, co-formulated with a potentially potent agent, zinc acetate for the
prevention of HIV infection in women. This is the first in-human of PC-1005 (MIV-150/zinc
acetate in a carrageenan gel), the first study in which females will be exposed to MIV-150,
the first time MIV-150 will be administered topically, and the first time MIV-150 will be
administered intravaginally.